Mirtazapine Teva (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing 5‑HT2 and 5‑HT3 receptors. This dual action boosts both noradrenergic and serotonergic neurotransmission, leading to an overall antidepressant effect.

The dosage of Mirtazapine Teva is individualized. A qualified prescriber determines the appropriate starting dose, titration schedule, and maintenance dose based on the patient’s clinical response, tolerability, and any co‑existing medical conditions.

Safety data for Mirtazapine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), Mirtazapine often produces more sedation and weight gain but may be advantageous for patients with insomnia or poor appetite. Its distinct receptor profile can be useful when SSRIs are ineffective or poorly tolerated.

Store the tablets at room temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Mirtazapine Teva is taken orally, usually once daily in the evening. Swallow the tablet whole with water; it may be taken with or without food, although taking it with food can reduce gastrointestinal discomfort.

Serious risks include agranulocytosis, severe neutropenia, seizures, suicidal thoughts or behaviors, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, and significant hepatic dysfunction. Patients should be monitored closely for any of these events.

Mirtazapine is contraindicated in patients who have taken a monoamine oxidase inhibitor (MAOI) within the past 14 days, those with known hypersensitivity to mirtazapine, and individuals with severe hepatic impairment. Caution is also advised for patients with a history of bipolar disorder or uncontrolled epilepsy.